Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth fact...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2012-12, Vol.136 (3), p.795-804
Hauptverfasser: Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., Arpino, G.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Biological and medical sciences
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer patients
Cancer research
Cancer therapies
Carcinoma, Ductal, Breast - genetics
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - mortality
Carcinoma, Ductal, Breast - pathology
Chemotherapy, Adjuvant
Clinical outcomes
Clinical Trial
Comparative analysis
ErbB Receptors - metabolism
Estrogen
Female
Follow-Up Studies
Genotype & phenotype
Gynecology. Andrology. Obstetrics
Humans
Long term
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Oncology
Ploidies
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Treatment Outcome
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger ( p  = 0.02), more proliferative (high S-phase 54 vs. 17 %, p  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-012-2315-y